Smartlab Europe
Production & Manufacturing

Eurogentec drug substance manufacturing facility wins FDA nod

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Business & Industry

Ensuring Regulatory Compliance in Pharmaceutical QC Labs

Ensuring regulatory compliance in pharmaceutical Quality Control labs requires advanced analytical capabilities, robust data integrity systems, and strict adherence to evolving global GMP standards. By integrating lifecycle-based method validation, digital traceability, and ultra-trace impurity detection, QC laboratories safeguard product quality and patient safety at every stage of manufacturing.
Business & Industry

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.
Business & Industry

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.
- Advertisement -

The FDA has granted acceptable status, under its current regulatory guidelines, to Eurogentec’s Seraing, Belgium drug substance manufacturing facility. The status will allow Eurogentec to manufacture a commercial bulk parenteral biopharmaceutical for one of its clients for the US market. Eurogentec CEO Jean-Pierre Delwart said they anticipate it as one of several future inspections as they work to bring other products closer to commercialization with their clients. Eurogentec Business Unit Director Ingrid Dheur said this demonstrates the strict cGMP compliant manufacturing and quality management system maintained at Eurogentec.

Latest stories

Previous article
Dainippon wins manufacturing approval for sleep inducing therapy in Japan
Next article
BioLife Solutions to build second GMP production facility

Related stories

Business & Industry

Ensuring Regulatory Compliance in Pharmaceutical QC Labs

Ensuring regulatory compliance in pharmaceutical Quality Control labs requires advanced analytical capabilities, robust data integrity systems, and strict adherence to evolving global GMP standards. By integrating lifecycle-based method validation, digital traceability, and ultra-trace impurity detection, QC laboratories safeguard product quality and patient safety at every stage of manufacturing.
Business & Industry

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.
Business & Industry

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.
Business & Industry

Managing PFAS Regulations in Pharmaceutical Supply Chains

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

About us

World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. . . Read More

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »
MORE STORIES
Periodontal disease risk factor systemic conditions

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Pharma navigating EPR split tier reality 2026

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing...